Matthew Krebs, Dr
The Christie Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Matthew Krebs, Dr as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:34 UTC. Open this list on ClinicalTrials.gov
- Ph2/Ph3NCT06988475 · DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET DysregulationsCancer Research UK · recruiting · Solid Tumour, Haematological Malignancy, Malignant Neoplasm · principal investigator
- Ph2/Ph3NCT05786716 · DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsCancer Research UK · recruiting · Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm · principal investigator
- Ph2/Ph3NCT05770037 · DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive CancersCancer Research UK · recruiting · Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders · principal investigator
- Ph2/Ph3NCT05770544 · DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.Cancer Research UK · recruiting · Haematological Malignancy, Malignancy, Malignant Neoplasm · principal investigator
- Ph2/Ph3NCT05770102 · DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) DispositionCancer Research UK · recruiting · Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders · principal investigator
- Ph2/Ph3NCT05768178 · DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.Cancer Research UK · recruiting · Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary · principal investigator
- Ph2/Ph3NCT05722886 · DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolCancer Research UK · recruiting · Haematological Malignancy, Solid Tumour · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 22 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.